PHYDIS (HONG KONG) BIOTECHNOLOGY CO., LIMITED – Trademark Portfolio

Entity Type: 99

PHYDIS (HONG KONG) BIOTECHNOLOGY CO., LIMITED holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include HRKC. The owner is based in KOWLOON.

ROOM 1508, 15 / F, ARAM CENTRE OFFICE

KOWLOON , HK

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

HRKC
HRKC
Registered 2020

Trademark Classifications

PHYDIS (HONG KONG) BIOTECHNOLOGY CO., LIMITED's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does PHYDIS (HONG KONG) BIOTECHNOLOGY CO., LIMITED have?

PHYDIS (HONG KONG) BIOTECHNOLOGY CO., LIMITED has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does PHYDIS (HONG KONG) BIOTECHNOLOGY CO., LIMITED file in?

PHYDIS (HONG KONG) BIOTECHNOLOGY CO., LIMITED files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are PHYDIS (HONG KONG) BIOTECHNOLOGY CO., LIMITED's most well-known trademarks?

PHYDIS (HONG KONG) BIOTECHNOLOGY CO., LIMITED's registered trademark portfolio includes well-known marks such as HRKC. These are among 1 currently registered trademark in the portfolio.

What is PHYDIS (HONG KONG) BIOTECHNOLOGY CO., LIMITED's trademark registration success rate?

PHYDIS (HONG KONG) BIOTECHNOLOGY CO., LIMITED has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.